ArticleAdvanced functional materials2025
Lipopeptide Hydrogel Possesses Adjuvant-Like Properties for the Delivery of the GPC-3 Peptide-derived Antigen.
Article in Advanced functional materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Fundamentals and Advances in Programmable Peptide Hydrogels for Multifunctional Biomedical Applications: A Review.Gels (Basel, Switzerland) · 2026Review
- Review
- Self-Assembling Hydrogels of Naproxen-Conjugated Peptides for Osteoarthritis Treatment.Theranostics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Peptide-based cancer vaccines are attractive as they can elicit antigen-specific cytotoxic T lymphocytes (CTLs) with minimal side effects. However, low immunogenic responses have delayed their translation to the clinic. Adjuvants, which are required in vaccines to boost immunogenicity, currently lack the ability to simultaneously induce specific cell-mediated effects and act as a delivery system. These concerns are addressed by engineering a novel class of adjuvants; lipopeptide hydrogels (LPHs). Myristic acid conjugated to diphenylalanine (Myr-FF), myristic acid diphenylalanine-tyrosine (Myr-FFY), and combination gel (Cogel) are synthesized and tested for immune modulation. They are loaded with a glypican-3 (GPC-3)-derived peptide designed for targeting hepatocellular carcinoma (HCC). The LPHs enable the sustained release of the GPC-3 peptide over two weeks, followed by antigen uptake by antigen-presenting cells (APCs). These LPHs are shown to act as a toll-like receptor (TLR)-2 agonist, cause an upregulation of costimulatory molecules (CD80, CD83, CD86), and the secretion of cytokines (IL-6, TNF-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.